Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma. Issue 5 (June 2015)

• Record Type: Journal Article
• Authors: Ranganath, Harsha A.; Panella, Timothy J.
• Is Part Of: Journal of immunotherapy. Volume 38:Issue 5(2015:Jun.)
• Publication Date: 2015-06
• Subjects: ipilimumab -- melanoma -- transplant -- metastatic melanoma -- immunotherapy -- CTLA-4 -- liver transplant -- immune therapy -- immunosuppression; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000077
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : The CTLA-4 immune checkpoint inhibitor ipilimumab improves overall survival in metastatic melanoma. Its use in organ transplant recipients has not been studied and has been reported once in the literature. We report the case of a 59-year-old liver transplant patient who was given ipilimumab after previous treatment for advanced melanoma. She did not experience organ rejection, immune-related adverse events, or evidence of tumor regression.